Something is happening in Washington that veterans should be paying attention to. Not because it is finished. Because it is moving.

In the last thirty days, three federal actions have moved the conversation on alternative treatments for veterans further than the previous fifty years.

April 18, 2026. President Trump signed an executive order directing the FDA to accelerate review of psychedelic therapies for serious mental illness. The order committed at least $50 million in federal funds to research on ibogaine, a Schedule I substance the federal government has classified alongside heroin since 1970. At the signing, the President read a statistic that should stop every veteran reading this email: since 9/11, the United States has lost over twenty-one times more veteran lives to suicide than to combat.

April 21, 2026. The DEA filed approval for the VA Cooperative Studies Program in Albuquerque to import marijuana extract and THC for clinical trials. This is the first time a VA research program has been authorized to handle Schedule I cannabis derivatives directly. The Cooperative Studies Program runs the largest network of VA clinical trials in the country.

April 23, 2026. The DEA finalized federal rescheduling of marijuana from Schedule I to Schedule III. After more than fifty years.

Three actions. Five days. None of them are finished. All of them matter.

I want to be careful about how I talk about this, because there is a lot of hype and a lot of bad information moving through the veteran community right now. Here is what I think is true.

What is real.

The VA is actively funding research into alternative treatments for the first time in a generation. In February 2026, VA researchers at Brown University and Yale launched the first VA-funded study of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder. This is the first VA-funded psychedelic study since the 1960s. A bipartisan Senate bill introduced in March would commit $30 million per year to establish psychedelic-focused Centers of Excellence at VA facilities, with research into psilocybin, MDMA, and ibogaine. A Stanford study published in January 2026 found that ibogaine, combined with magnesium for cardiac safety, significantly reduced PTSD, anxiety, and depression symptoms in special operations veterans with traumatic brain injury and blast exposure, with no serious adverse events reported.

This is not advocacy talking. This is the federal government, peer-reviewed research, and bipartisan legislators all moving the same direction at the same time. It is the strongest signal in fifty years that the institutional posture is shifting.

What is still true.

VA physicians cannot recommend cannabis. VA pharmacies cannot dispense it. The VA will not pay for medical marijuana from any source. VHA Directive 1315 still controls. Veterans who use cannabis for service-connected conditions still need to document it with private providers, not VA primary care.

The VA's National Center for PTSD, in its current clinical guidance, recommends against the use of cannabis for PTSD treatment, citing studies showing potential for harm with long-term use. This is the official VA position as of today. The newer research on psychedelics and structured therapy with MDMA is following a different evidentiary path. The two should not be conflated.

The Canadian comparison.

In fiscal year 2025–26, Veterans Affairs Canada reimbursed 31,230 veterans for medical cannabis at roughly six dollars a gram. The program has run for over a decade. Cross the border and the policy gap is no longer theoretical. It is administrative, and it is closing slowly, in the United States, through clinical trials and bipartisan legislation rather than direct policy reversal.

What veterans should do with this information.

Stay informed. The pace of change is accelerating, and the next twelve months are likely to bring more federal movement, not less.

Stay skeptical of the hype. There is a vocal community of advocates, treatment centers, and entrepreneurs who are running ahead of the science. The science is real. It is also early. Phase 2 and Phase 3 trials are how we will know what actually works, for whom, and at what dose. We are not there yet.

If you are struggling, do not wait for the policy to catch up. Get to a primary care appointment. Document everything. The treatments available today inside the VA — including evidence-based therapies for PTSD that the VA does pay for and does deliver — are still the foundation. The new research is layering on top of that foundation, not replacing it.

If you or someone you love is in crisis or having thoughts of suicide, contact the Veterans Crisis Line by dialing 988 and pressing 1, by texting 838255, or by chatting at VeteransCrisisLine.net. You are not alone.

What I am watching next.

The MAPS Phase 2 cannabis trial for PTSD now recruiting (NCT07224698). The first results from the VA-Brown-Yale MDMA study expected within 18 months. The Senate Centers of Excellence bill, if it advances. Whether the House moves on legislation that would explicitly allow VA physicians to recommend cannabis in legal states. And whether any of these legislative threads survives the next budget cycle.

This is the work. This is what WarriorWay is here to track for you, every Tuesday.

Reply and tell me one thing. Are you seeing this conversation come up in your circles? What is your read? I read every reply, and the conversations shape what I write next.

If this issue helped, forward it to one veteran who would benefit. The free 3-Pillar VA Claim Checklist is still available at warriorway.co.

Wake up the warrior. Push through. Get it done.

— Michael WarriorWay